# Remifentanil Target Controlled Infusion Versus Standard of Care for Conscious Sedation During EBUS-TBNA

> **NCT06033729** · NA · COMPLETED · sponsor: **Scarlata, Simone, M.D.** · enrollment: 30 (actual)

## Conditions studied

- Lung Cancer
- Lung; Node
- Sedation Complication
- Endoscopy

## Interventions

- **DRUG:** Remifentanil TCI
- **DRUG:** Midazolam injection
- **DRUG:** Fentanyl
- **DRUG:** Propofol

## Key facts

- **NCT ID:** NCT06033729
- **Lead sponsor:** Scarlata, Simone, M.D.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-20
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-01-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06033729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06033729, "Remifentanil Target Controlled Infusion Versus Standard of Care for Conscious Sedation During EBUS-TBNA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06033729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*